Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIMEMA LAL1913: Peg-ASP in Adult Ph- ALL
NCT02067143Phase 2Completed
- Sponsor
- GIMEMA
- Start
- May 2014
- Primary completion
- Oct 2016
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by GIMEMA. Primary endpoint: Disease Free Survival at 2 years. Started May 2014; status: completed.
02
Drugs
pegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02067143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067143.